Mobius Therapeutics, LLC

Mobius Therapeutics is a leading ophthalmic company based in Saint Louis, MO, offering the FDA-approved Mitosol, a groundbreaking formulation of ophthalmic MMC. With its closed-system transfer device and compliance with USP 800 standards, Mitosol sets a new standard of care in glaucoma surgery, providing immediate and precise reconstitution, room temperature storage for up to 24 months, and patented closed-system preparation and disposal.

As the only formulation of ophthalmic MMC approved by the FDA, Mitosol is indicated as an adjunct to ab externo glaucoma surgery, offering a total package upgrade in the standard of care. However, it is important to note that Mitosol is contraindicated in patients with a hypersensitivity to mitomycin and may cause adverse reactions such as hypotony, cataract development, and embryo-fetal toxicity. For more information, please refer to the full product information and consult a healthcare professional.

Generated from the website